DNA Repair Protein HELQ and XAB2 as Chemoresponse and Prognosis Biomarkers in Ascites Tumor Cells of High-Grade Serous Ovarian Cancer

Table 3

Clinicopathologic characteristics of 32 HGSC patients in validation cohort.

Clinicopathologic parameters	Frequency (%)	Expression level in ascites tumor cells
		HELQ			XAB2
		High	Low		High	Low
Age (year)				0.590			0.590
≤60	25 (78)	4	21		4	21
>60	7 (22)	2	5		2	5
FIGO stage				1.00			1.00
I-II	1 (4)	0	1		0	1
III-IV	31 (97)	6	25		6	25
Residual disease				0.049			0.040
R0	13 (41)	0	13		0	13
R1	12 (38)	4	8		4	8
>R1	6 (19)	1	5		2	4
Ascitic fluid (ml)				0.361			0.059
≤500	13 (41)	1	12		0	13
>500	19 (59)	5	14		6	13
Chemotherapy response				0.012			0.101
Sensitive	25 (78)	2	23		3	22
Resistant	7 (22)	4	3		3	4

With one patient whose residual disease was unavailable. HGSC: high-grade serous ovarian cancer; FIGO: International Federation of Gynecology and Obstetrics.